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nigral tissue in affected areas of the brain. Open label
human trials and animal experiments have shown that
implanted fetal nigral tissue can survive after transplan-
tation, reinervate affected areas of the brain, and have
a positive effect of PD symptoms (Freeman et al., 1999).
Based on these results, the National Institutes of Health
(NIH) funded two randomized, double blind, placebo
controlled, fetal nigral transplantation studies random-
ized controlled trials (RCTs), in the in the mid-1990s after
the ban on federal funding for fetal tissue research was
lifted. The placebo arm of the studies consisted of sham
surgery, which involved the drilling of burr holes
through skull but not past the dura. Follow-up care for
the placebo group was the same as for the active group
in one of the studies, involving low doses of
cyclosporine and positron emission tomography (PET)
imaging at various stages in the study (Freeman et al.,
1999). Follow-up care in the other study did not involve
immunosuppressive drugs (Freed et al., 2001). The first
study, begun in 1993 and conducted at the University of
Colorado by Curt Freed and Columbia University by
Stanley Fahn, published its results last spring. Results for
the second study, begun in 1995, were published this
past September. 
The results of the Colombia/Colorado study showed
some promising improvement with transplantation.
Patients were evaluated on a subjective scale, which
they graded themselves, and on a variety of objective
assessments preformed by the research staff. All these
evaluations were done throughout the year after their
surgery. The results of these evaluations showed improve-
ment in the transplant group compared with the placebo
group. But along with the positive results severe
dystonia and dyskinesia were noted after one year in 5
of the 33 (15%) patients in the active arm of the study
(Freed et al., 2001). The second study, which used the
change in the subjects score in the motor component of
the Unified Parkinson’s Disease Rating Scale between
baseline and final visits as its primary endpoint, failed to
demonstrate a significant overall treatment effect. Addi-
tionally, 56% of the transplanted patients developed
dyskinesia that persisted after withdrawal of dopamin-
geric medication (Olanow et al., 2003).
INFORMED CONSENT
Individuals’ consent for participation in clinical trials has
been at the forefront of biomedical ethics since the
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ABSTRACT
Fetal cellular transplantation therapy research in
Parkinson’s Disease has raised important ethical ques-
tions from its beginning. One of the most hotly debated
aspects of the recent clinical research has been the use
of sham surgery as a placebo for the control group. Ethi-
cists and researchers have focused on the unique risk
surgical placebos pose to research subjects as compared
to conventional, medical placebos. This review will deal
with informed consent and the use of use of sham
surgery in the placebo arm of  recent fetal tissue trans-
plantation randomized, placebo controlled, double
blind, clinical trials. Do current procedures for obtaining
informed consent meet the challenge of adequately
informing patients enrolling in experiments with signifi-
cant risks not only in the experimental group but also in
the placebo group?
INTRODUCTION
Parkinson’s Disease (PD) is a disorder of movement char-
acterized by bradykinesia, “resting tremor,” postural
changes, and instability. Pathologically, PD is due to a
loss of dopiminergic neurons in the substantia nigra pars
compacta, other pigmented nuclei of the brainstem, and
the basal ganglia. The disease is common, affecting
approximately 1 million people in North America, about
1% of the population over age 65 (Victor and Ropper,
2001).
Current treatment for PD involves both medical and
surgical approaches, with medical management being
the most widely used. Effective medical treatment
usually constitutes dopamine replacement therapy using
dopamine receptor agonists or dopamine precursors,
most notably L-dopa. Surgical therapy can be either
ablative or stimulatory, generally with the same targets.
Both medical and surgical therapies can offer substantial
improvement for a period of time but their effectiveness
eventually wanes, often coinciding with an upswing in
side effects. In the case of L-dopa therapy, severe side
effects include dystonia, dyskinesia, nausea and
vomiting, and the possibility of drug induced psychosis. 
NOVEL APPROACHES TO THE TREATMENT OF
PARKINSON’S DISEASE
One of the most promising approaches towards the
treatment of PD has been the transplantation of fetal
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Nuremberg Trials detailed the horrifying abuse of pris-
oners in Nazi concentration camps for medical research
purposes during World War II. In the years, since,
informed consent in the research setting has evolved to
serve two purposes. It was originally developed as a
mechanism to ensure the protection of research subjects
from undue risk and exploitation. In later years, it has
become a central component in the concept of patient
and research subject autonomy in medical decision-
making (Beauchamp and Childress, 2001; Meisel and
Kuczewski, 1996). Although the ideal of informed
consent has been well established in the medical
community, research dating back to the late 1960s has
shown that its goals are rarely attained. Researchers
have detailed problems with informed consent in
research regarding: 1) patient and research subject
understanding of the procedures and/or trials they have
consented to and their associated benefits and risks; 2)
the complexity and length of consent forms; and 3)
patient and research subject understanding about the
nature of informed consent – its purpose in informing
patients and research subjects about the procedures or
research they are consenting to and providing them
with an account of the options available to them. 
RESEARCH SUBJECT UNDERSTANDING OF CLINICAL
TRIALS AND PROCEDURES
Significant numbers of subjects in studies regarding the
quality of informed consent have been unable to articu-
late important aspects of their consent when tested
about them. In one study of cancer patients enrolled in
a Phase I clinical trials, only 33% of the participants
interviewed were able to state the purpose of the trial
(Daugherty et al., 1995). Other studies have also found
sizable percentages of research subjects without an
adequate level of understanding of the procedures they
had consented to or the projects they had enrolled in. In
these studies, research subject comprehension ranged
from a little over 50% to almost 75% (Byrne et al., 1988;
Cassileth et al., 1980; Lynoe et al., 1991). According to
these figures, at the very least one-quarter of all
research subjects do not understand or do not recall
what they have consented to. If it is the first, lack of
understanding, then those subjects do not meet the
ethical criteria for what is considered “informed.” The
con-founding factor is subject recall. 
Differentiating between recall and understanding has
been problematic in informed consent research and the
literature is ambiguous about research subjects’ ability
to retain information. Problems with long term recall
and comprehension were noted in one study as research
subjects’ average score on a test of their recall and
understanding declined from 71.6% immediately after
enrollment to 61.2% after 3 months (Bergler et al.,
1980). Compounding the problems of recall versus
understanding are findings suggesting that research
subjects with differing severity of disease retain
different information over periods of time. An examina-
tion of subjects recall over time showed that healthy
subjects, or those with a less severe diagnosis, retain the
most information regarding a clinical trial’s purpose,
benefits, and risks, while sicker subjects tended to retain
the most information regarding a study’s procedures
(Schaefffer et al., 1996). The most relevant finding of
this study was that the changes in recall and under-
standing do not always decrease over time. Sicker
subjects displayed an increase in their recall and under-
standing of purposes, benefits, risks, and procedures
over a four to six week period, while healthier subjects
displayed only a small decrease. These findings led the
authors to assert that research subjects were able to
retain information over a six-week period without a
significant decline and possibly a slight increase, thus
casting into doubt the assumption that research subjects
do not retain much of what they hear or read. Since the
most notable studies regarding research subject under-
standing of informed consent tended to conduct their
interviews within a much shorter time frame, it would
appear that research subject understanding, not recall,
is the major problem with informed consent. 
In clinical trials the problem of poorly informed subjects
is compounded by the fact that their participation will
not definitely benefit them even though therapeutic
benefit is often cited as their most important reason for
participation. In the study of cancer patients in Phase I
trials mentioned previously, 85% cited therapeutic
benefit as their main reason for participation. Research
has placed tumor response rates at 4% to 6% in phase I
trials. No subjects in that same study mentioned altruism
as their primary reason for participation (Daugherty et
al., 1995). 
In addition many studies have found that research
subjects often recall the possible benefits of their partic-
ipation with greater frequency and accuracy than the
risks. One study of research subjects suffering from
acute coronary syndromes employed a scoring system to
ascertain subjects’ knowledge of the clinical trial they
were participating in. Within 14 hours of the consent
process, the mean score for understanding of the
possible benefits was 85%, while the mean score for
possible risks was 35% (Kucia and Horowitz, 2000). In
the Columbia/Colorado fetal nigral transplantation
study, some subjects in the placebo group felt misled
after the study had ended when they were told that
they would not be eligible for the real transplant proce-
dure due to safety concerns. “This response exemplifies
the ‘therapeutic misconception’ – the all too common
assumption that research promises beneficial treatment,
even in its earliest phases” (Macklin, 1999). The “thera-
peutic misconception” and research subjects’ tendency
to emphasize benefits over risks have been cited as an
important barrier to informed consent in clinical trials
(Applebaum et al., 1991). 
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It is important to note that a poor consent process is not
the only reason behind the “therapeutic misconception”
and the emphasis of benefits over risks among research
subjects. In a study examining the feelings healthy
patients had towards participating in clinical research,
the researchers found that a significantly small number
of people expressed interest in participating in trials
involving experimental medications (Dazzi et al., 2001).
This led the authors to reasonably assert that many
patients who agree to participate in clinical trials do so
for expected personal gain, or else there would be many
fewer subjects participating in research today. Although
poor communication on the part of medical personnel
and the complexity of the material presented are often
indicated as causes of poorly informed research subjects,
these findings suggests that research subjects are also
complicit in their lack of comprehension.
CONSENT FORMS
Along with the “therapeutic misconception” and
research subjects desire to experience benefits rather
than risks, another reason often cited as a cause of
poorly informed research subjects and patients, in both
clinical trials and therapeutic procedures requiring
consent, is the complexity and length of consent forms
(Cassileth et al., 1980). A study dealing specifically with
the length of consent forms found that comprehension
of the forms was inversely related to the forms’ length.
Of research subjects given consent forms of varying
length (short, medium, and long), those with the short
form demonstrated the highest level of comprehension
and those with the long form demonstrated the lowest
level. In addition, all subjects given the shortest form
felt the information was useful, while 23% of the
subjects given the medium length form felt the informa-
tion was either frightening or not useful. Forty-one
percent of the subjects given the longest form felt the
information was either frightening or not useful
(Chaikin and Lasagna, 1969). 
Another study dealing with the complexity of consent
forms found that consent forms were only slightly less
difficult to understand than medical journals, but much
more difficult than popular media (Morrow, 1980). This
finding led the authors to reasonably assert that
although consent forms may thoroughly provide all the
information required to inform research subjects, their
complexity is most likely to be an important barrier to
actually informing research subjects. 
Examination of consent forms has also shown that the
“therapeutic misconception” is not simply due to
research subjects’ desire to experience benefits more
than risk, but is sometimes encouraged by the consent
forms themselves. The Advisory Committee on Human
Radiation Experiments, in their study of the United
States government’s human subject radiation experi-
ments during the Cold War and their review of current
ethical issues surrounding human subject research,
found that consent forms often overstate the benefits
of research. “The consent forms to be used with such
patient-subjects sometimes appeared to suggest a
greater prospect of benefit than the research as
described in the documents we reviewed warranted. In
a few Phase I studies, any intimation that subjects would
benefit appeared questionable (United States Advisory
Committee on Human Radiation Experiments, 1996). It is
impossible for subjects to accurately inform themselves
about their participation in research if they are not
given a complete and honest account of the possible
benefits and risks. The literature has shown that the
complexity of consent forms along with their length and
their often inaccurate statements regarding the possible
benefits and risks of participation in research imposes a
great burden on research subjects, as well as a barrier to
understanding.
PATIENT UNDERSTANDING OF INFORMED CONSENT
Compounding problems with consent forms is the view,
among patients and research subjects, that the consent
process and forms are risk management tools for hospi-
tals, not methods for informing patient’s and research
subject’s decision-making. Some medical and research
staff also share this view (Miesel and Kuczewski, 1996).
Cassileth et al., in a study of recall and understanding of
informed consent in post-operative patients, found that
75% of all patients interviewed believed that consent
forms were used to protect physicians’ rights while only
about 50% of patients believed they were used to
protect patients’ rights. Only 43% of the participants in
the study believed that consent forms were meant as
“explanations of treatment” (Cassileth et al., 1980). It is
important to note that this study dealt specifically with
consent to treatment not to participate in research, but
the main point, that patients often misunderstand the
purpose of informed consent, can be applied to all
consent forms and processes including those used in
research. 
Since their advent, consent forms in research have been
meant as tools to protect research subject rights and
promote autonomy (Beauchamp and Childress, 2001).
The fact that 50% or less of research subjects may not
understand this creates an immense barrier to truly
informing patients, as they might not use the consent
process to inform themselves about what they have
agreed to do, but instead focus on it as process to lessen
physicians’ legal risks. 
IMPLICATIONS FOR FETAL NIGRAL TISSUE TRANSPLAN-
TATION RESEARCH
Freeman et al. (1999), in their defense of the use of
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placebo surgery in fetal tissue transplantation RCTs,
argue that the risks and benefits of participating in the
trial, either in the transplant group or, more impor-
tantly, the placebo group are reasonable. The risks
involve the actual sham surgery, including the use of
general anesthesia and follow-up care, which involves
the administration of cyclosporine at low doses and the
use of radioisotopes for PET imaging. The benefits
include the potential for contributing to advances in
treatment of the disease and the possibility of under-
going the procedure if it is proved safe and effective. To
further cement their claim of a reasonable risk to
benefit analysis, they cite the approval of their Institu-
tional Review Board’s (IRBs), the NIH, and the consent of
participants in the research. 
Macklin (1999) has argued that informed consent alone
does not meet the ethical requirements of human
subject research. She notes that researchers have an
obligation to minimize the risks to their subjects and it
is the charge of IRBs to enforce this. Freeman et al.’s
position can be further questioned when the literature
documenting the problems with informed consent is
taken into account. To claim as they do, that the
approval of the risk benefit analysis by subjects enrolled
in their research in part validates the ethics of placebo
surgery, circumvents the entire purpose of an ethical
approach to human subject research, of which informed
consent is one of its main foundations.
When research subjects give their consent to participate
in research, they acknowledge that they have weighed
the risks and benefits as they have been presented to
them and judged them to be acceptable. Research has
demonstrated that many research subjects informed in
a conventional consent process do not fully compre-
hend the nature of their consent, the procedures of the
trial they have entered, all the risks associated with it,
and  the reality that their chance of receiving benefit is
often quite small. Regardless of these problems, the
research community has deemed the informed consent
process, as it currently stands, acceptable for patients
entering medical placebo controlled RCTs. But there is a
fundamental difference between medical placebo
controlled RCTs and the ones used for PD fetal tissue
transplantation research. The placebo arm of the
former uses inert and innocuous substances or proce-
dures, while that of latter use potentially harmful
surgical procedures, anesthesia, and post-operative
care. Extensive research has shown that a significant
number of subjects involved in clinical research do not
fully comprehend the nature of their participation on
many levels. It would be unfair for researchers and IRBs
to assume that current informed consent procedures
adequately protect subjects involved in research that
uses sham surgery as a placebo, since there is a 50%
chance that the patient will be put at significant risk
without receiving any experimental therapy and, there-
fore, have no chance of benefit.
THE FUTURE
If current consent procedures are not adequate to meet
the ethical requirements of enrolling subjects in trials
that use sham surgery as a placebo arm, what can be
done? An ideal approach would target the areas of
informed consent that help create a barrier to true
patient understanding.
An important target for an enhanced consent process
would be the “therapeutic misconception.” Applebaum
et al. (1991) propose a novel procedure where a neutral
discloser, not a member of the research team, conducts
the consent process, emphasizing not only the research
but how research differs from treatment. In their
research with this type of consent process the results
were promising. They noted substantial changes in the
percentage of subjects who understood the various
components of research (randomization, placebos, etc.)
as compared to the subjects who participated in the
normal consent process. Other ideas include quizzing
subjects on the information provided them during the
consent process to further reinforce what was said or
read and using a standard script to ensure the informa-
tion provided is complete and not dependent on the
subject’s effort to learn about the research (Reicken and
Ravich, 1982).
The legalistic nature of the forms and process is another
area in which improvement might be made (Cassileth et
al., 1980). That some research subjects mistakenly feel
that the consent forms and process are simply risk
management tools for physicians and hospitals prevents
those subjects from using the consent process as a tool
to ensure they are informed about their decisions. This
is not just a problem for research subjects. Many physi-
cians also see consent forms as risk management tools
(Meisel and Kuczewski, 1996). Although most researchers
and IRBs probably understand the purpose of consent
forms, it is imperative that all members of the research
staff understand that consent forms are first and fore-
most a tool to insure research subject autonomy and that
this understanding is passed on to potential subjects.
Additionally, problems with the length and complexity
of consent forms have been cited by various studies as
real barriers to informing research subjects. This is an
area where improvements can easily be made. IRBs and
researchers can work to insure that not only are consent
forms accurate and complete but that they are as brief
as possible (without sacrificing important information)
and that they are written on the same level as easily
understandable popular media.
CONCLUSION
Informed consent in research is one of medicine’s most
powerful tools in ensuring that the autonomy of
18 EJBM, Copyright © 2003
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research subjects is protected. It is imperative that every
effort be made to inform subjects, in terms they can
easily understand, about the research they participate
in. This becomes even more important when research
subjects may be exposed to physical risk without any
obvious medical benefit, as in the case of subjects
assigned to the placebo arm of fetal tissue transplanta-
tion studies. To assume that research subjects have exer-
cised their autonomy by signing a form or agreeing to
participate in research (without ensuring that every
effort has been taken to inform them of all the poten-
tial consequences, both good and bad) would be an
abdication of our responsibility to the ethical practice of
medicine. 
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